Seaport Therapeutics, Inc. Common Stock
SPTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.29B
Close$
$1.06
95.7% downside
Current Fair Value
95.7% downsideOvervalued by 95.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.29 Billion |
|---|---|
| Enterprise Value | $1.23 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.94 |
| Beta | 1.13 |
| Outstanding Shares | 53,530,550 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -14.57 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 3.56 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
$-0.62
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 70.07%▲ 70.07% |
|---|---|
| Total Invested | $815.97M |
| Investors Holding | 55▲ 55.00% |
ESG Score
No data
About Seaport Therapeutics, Inc. Common Stock
54 employees
CEO: Daphne Zohar Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling dis...